Want to see FTH full AI Analyst Report?
Faeth Therapeutics (FTH) AI Stock Analysis
Faeth Therapeutics
(NASDAQ:FTH)
The score is held down primarily by weak financial performance (pre-revenue profile, sharply higher TTM losses, and ongoing cash burn) and bearish technicals (below key moving averages with negative MACD). Low leverage and positive board-level expertise additions provide some support, but valuation metrics are not compelling given losses and no dividend.
Faeth Therapeutics (FTH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $515.32M
- Dividend Yield
- ―
- Average Volume (3M)
- 364.24K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.20
- Revenue Growth
- ―
- EPS Growth
- -624.45%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Faeth Therapeutics Business Overview & Revenue Model
Company Description
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-...
How the Company Makes Money
Public, verifiable details about Faeth Therapeutics’ revenue model and current revenue streams (e.g., product sales, licensing income, collaboration revenue, or service revenue) are null. As a result, a factual description of how the company currentl...
Faeth Therapeutics Financial Statement Overview
Summary
Overall fundamentals are weak: the company is pre-revenue with heavy and sharply worsening TTM losses and persistent cash burn (negative operating and free cash flow). The main offset is a relatively strong balance sheet with very low debt, but ongoing losses raise future financing/dilution risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -132.97M | 0 | -551.00K | -571.00K | -1.81M | -685.00K |
| EBITDA | -212.96M | -20.91M | -28.75M | -35.61M | -47.02M | -35.44M |
| Net Income | -211.36M | -21.09M | -30.16M | -34.10M | -48.59M | -36.79M |
Balance Sheet | ||||||
| Total Assets | 178.95M | 22.90M | 45.36M | 74.37M | 118.38M | 153.22M |
| Cash, Cash Equivalents and Short-Term Investments | 174.79M | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M |
| Total Debt | 145.00K | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M |
| Total Liabilities | 11.09M | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M |
| Stockholders Equity | 167.86M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M |
Cash Flow | ||||||
| Free Cash Flow | -43.28M | -20.47M | -24.82M | -32.20M | -39.35M | -32.28M |
| Operating Cash Flow | -43.27M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M |
| Investing Cash Flow | -137.25M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M |
| Financing Cash Flow | 184.14M | -645.00K | -787.00K | -11.17M | -287.00K | 163.94M |
Faeth Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTH, the sentiment is Negative. The current price of 19.99 is below the 20-day moving average (MA) of 20.26, below the 50-day MA of 27.95, and below the 200-day MA of 25.28, indicating a bearish trend. The MACD of -2.33 indicates Negative momentum. The RSI at 40.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FTH.
Faeth Therapeutics Risk Analysis
Faeth Therapeutics disclosed 82 risk factors in its most recent earnings report. Faeth Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskFaeth Therapeutics Peers Comparison
Overall Rating
CLRB47Neutral
COCP45Neutral- FTH42Neutral
BOLT40Underperform
BRTX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CLRB | 47Neutral | $12.38M | -0.27 | -165.71% | ― | ― | 77.68% |
| COCP | 45Neutral | $20.61M | -1.26 | -207.47% | ― | ― | 38.55% |
| FTH | 42Neutral | $507.76M | -0.14 | -155.46% | ― | ― | -624.45% |
| BOLT | 40Underperform | $12.66M | -0.41 | -126.23% | ― | 12.79% | 37.93% |
| BRTX | 38Underperform | $2.04M | -0.07 | -423.84% | ― | -8.47% | 25.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | 19.99 | 10.65 | 114.03% | |
| CLRB | Cellectar Biosciences Inc | 1.23 | -2.20 | -64.14% | |
| COCP | Cocrystal Pharma | 1.01 | 0.00 | 0.00% | |
| BRTX | Biorestorative Therapies, Inc. | 1.51 | -26.49 | -94.61% | |
| BOLT | Bolt Biotherapeutics, Inc. | 6.54 | 1.76 | 36.82% |
Faeth Therapeutics Corporate Events
Faeth Therapeutics Adds Oncology Expert to Board
PositiveOn October 23, 2026, Faeth Therapeutics, Inc. expanded its Board of Directors from six to seven members and appointed Adam Schayowitz, Ph.D., as a Class III director, with his term running until the 2027 annual meeting of stockholders unless ended ea...
Faeth Therapeutics Adds Cancer Expert to Board
PositiveOn September 11, 2026, Faeth Therapeutics, Inc. expanded its Board of Directors from five to six members and appointed company co-founder and cancer biologist Karen Vousden, Ph.D., as a Class II director, with her term running until the 2029 annual m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026